Charles Hill, MD
Internal Medicine · Oxford, MSNPI 1871600189
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 1,064 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,064 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Pfizer$1K
- Boehringer Ingelheim$1K
- plus $7K from 46 others
What the payments were for
- Food & beverage$14,94298%
- Education$3252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$15,267 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 251 | $254,441 |
| EliquisApixaban | 209 | $170,433 |
| JardianceEmpagliflozin | 219 | $161,996 |
| FarxigaDapagliflozin Propanediol | 192 | $143,132 |
| XareltoRivaroxaban | 124 | $92,644 |
| JanuviaSitagliptin Phosphate | 100 | $71,652 |
| Tresiba Flextouch U-200Insulin Degludec | 101 | $70,124 |
| TradjentaLinagliptin | 67 | $57,336 |
| MounjaroTirzepatide | 47 | $46,304 |
| TrulicityDulaglutide | 48 | $44,617 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $42,043 |
| LinzessLinaclotide | 47 | $37,516 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 43 | $33,257 |
| GlyxambiEmpagliflozin/Linagliptin | 32 | $32,056 |
| MyrbetriqMirabegron | 69 | $31,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr, Synjardy Xr | $1,004 | $299,859377 claims |
| Novo NordiskOzempic | $1,546 | $254,441251 claims |
| PfizerEliquis | $1,144 | $170,433209 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Byetta | $1,490 | $167,452222 claims |
| MerckJanuvia, Janumet Xr, Janumet | $377 | $122,381164 claims |
| Johnson & JohnsonXarelto | $664 | $92,644124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,316 | $90,92195 claims |
| AbbVieLinzess, Synthroid | $1,809 | $49,224217 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $272 | $42,20859 claims |
| Astellas Pharma US IncMyrbetriq | $591 | $31,21969 claims |
| NovartisEntresto | $607 | $25,10237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Oxford
- Jeffrey DennisOxford$15K
- Milton HobbsOxford$8K
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- Paul VolanskyCorinth$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.